Microdosing Psilocybin: Benefits, Risks, and What Science Says

What Is Microdosing?

Microdosing psilocybin refers to the practice of consuming very small, sub-perceptual doses of psilocybin-containing mushrooms on a regular schedule. Unlike full psychedelic doses that produce profound altered states of consciousness, microdoses are intended to be subtle — users should not experience hallucinations or significant perceptual changes.

Typical microdosing protocols involve taking a dose every 3-4 days, following schedules popularized by researchers like James Fadiman. The most common regimen is "one day on, two days off," repeated for several weeks.

Reported Benefits

The microdosing community reports a wide range of benefits:

Mental Health

Reduced symptoms of depression and anxiety

Improved emotional regulation

Greater sense of well-being and life satisfaction

Cognitive Performance

Enhanced creativity and divergent thinking

Improved focus and concentration

Greater problem-solving ability

Social and Interpersonal

Increased empathy and emotional intelligence

Better social interactions

Reduced social anxiety

What Does the Research Say?

The Placebo Problem

The most significant challenge in microdosing research is the placebo effect. A landmark 2021 study by Szigeti et al. used an innovative self-blinding methodology where participants prepared their own placebo and active capsules. The results showed that while participants reported improvements, these were not significantly different between active psilocybin and placebo groups.

This finding suggests that much of microdosing's reported benefit may stem from expectation rather than pharmacological effects.

Controlled Studies

Several controlled studies have been conducted:

Bershad et al. (2019) — Low doses of LSD (6.5-26 mcg) produced dose-dependent effects on mood but no cognitive enhancement

Family et al. (2020) — Microdoses of LSD appeared to increase pain tolerance but did not enhance creativity measures

University of Chicago studies — Multiple trials found minimal cognitive or emotional benefits at sub-perceptual doses

Research indexed on PsiHub continues to explore whether specific subpopulations may benefit more from microdosing.

Potential Mechanisms

If microdosing does have genuine effects, proposed mechanisms include:

Low-level 5-HT2A stimulation — Subtle serotonin receptor activation without triggering full psychedelic effects

Neuroplasticity promotion — Even sub-threshold doses may stimulate BDNF and synaptic growth

Anti-inflammatory effects — Psilocybin may have immunomodulatory properties at low doses

Risks and Concerns

Despite its popularity, microdosing carries real risks:

Legal status — Psilocybin remains a Schedule I substance in the US and is illegal in most countries

Cardiac risk — Chronic 5-HT2B receptor activation could theoretically promote cardiac valvulopathy (similar to fenfluramine)

Dose consistency — Natural mushrooms vary significantly in psilocybin content

Psychological risks — Even low doses may exacerbate anxiety or psychotic symptoms in vulnerable individuals

Unknown long-term effects — No studies have examined regular microdosing beyond several months

The Legal Landscape

Microdosing exists in a legal gray area in most places. Some exceptions:

The Netherlands — Psilocybin truffles (sclerotia) are legal to purchase

Jamaica — No laws prohibiting psilocybin mushrooms

Oregon and Colorado — Regulated psilocybin services (though not specifically for microdosing)

Check substance legal status on PsiHub's substance pages.

Recommendations

Based on current evidence:

Claims about microdosing benefits should be viewed with healthy skepticism

The placebo effect likely accounts for a significant portion of reported benefits

Anyone considering microdosing should be aware of legal risks and potential health concerns

More rigorous, large-scale clinical trials are needed

Explore more research on psilocybin on PsiHub.

References

Szigeti, B. et al. (2021). Self-blinding citizen science to explore psychedelic microdosing. eLife.

Anderson, T. et al. (2019). Microdosing psychedelics: personality, mental health, and creativity. Psychopharmacology.

View all microdosing research on PsiHub